The Patent Finder

Shenzhen Optimum Biological Technology Co., Ltd.

8 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jul 14, 2027
    The maintenance fee for Cyclic Compound Acting as PDE4 Inhibitor (US 10,532,986) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,532,986Cyclic Compound Acting as PDE4 Inhibitor
In force
 · High confidence
In forceHigh confidence
US 11,136,315CXCR2 Antagonist
In force
 · High confidence
In forceHigh confidence
US 11,459,323Monocyclic B-Lactam Compound for Treating Bacterial Infection
In force
 · High confidence
In forceHigh confidence
US 12,338,218Crystal Form of BENZIMIDAZOLE-2-ONE Compound, Solvate Thereof, Crystal Form of Solvate Thereof, and Preparation Method Thereof
In force
 · High confidence
In forceHigh confidence
US 12,310,948Application of Monocyclic ß-Lactam Compound in Pharmacy
In force
 · Medium confidence
In forceMedium confidence
US 12,491,180Application of Compound in Treating Pneumonia
In force
 · Medium confidence
In forceMedium confidence
US 12,679,845Crystal Form of Triazolopyridine-Substituted Indazole Compound and Preparation Method Therefor
In force
 · High confidence
In forceHigh confidence
US 12,577,235Crystalline Form of CXCR2 Antagonist and Application Thereof
In force
 · High confidence
In forceHigh confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited